GSTM1 and chronic kidney disease: In conclusion, hyporesponsiveness to ESA, which is associated with a risk for renal and CVD events in patients with ND-CKD, may be directly evaluated as the dose of DA divided by the Hb level at the 12-week DA treatment, with a cut-off value of 5.2.